New drug shows promise for kidney disease patients
NCT ID NCT04663204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damage, and protect kidney function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sparsentan
What this could lead to
If successful, sparsentan could offer a new treatment option to slow kidney damage in people with IgA nephropathy, potentially delaying or avoiding dialysis or transplant.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals NHS Trust
RECRUITINGCambridge, England, United Kingdom
-
King's College Hospital
RECRUITINGLondon, United Kingdom
-
Leicester General Hospital, University Hospitals of Leicester NHS Trust
RECRUITINGLeicester, LE5 4PW, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northern Care Alliance NHS Foundation Trust - Salford Royal
RECRUITINGSalford, England, United Kingdom
-
Royal Infirmary of Edinburgh & Western General Hospital
RECRUITINGEdinburgh, Scotland, United Kingdom
-
University Hospital of wales
RECRUITINGCardiff, Wales, CF14 4XW, United Kingdom